An Ebola vaccine being developed by British pharmaceutical giant GlaxoSmithKline has been deemed safe enough to be trialled soon. Healthy individuals in West African countries, where the virus has rampaged, will be the first to participate. In an announcement reported by the Associated Press, Marie-Paule Kieny, the assistant director general of Health Systems and Innovation at the World Health Organization, revealed that both the GSK vaccine and one licensed by Merck and NewLink, have "an acceptable safety profile." According to Kieny, who is helping coordinate the hunt for an Ebola vaccine, six-month-long trials will begin in West Africa and health workers could be among the first to receive it. Doctors, nurses and volunteers continue to put themselves in harm's way everyday in affected areas of Sierra Leone, Guinea and Liberia, with WHO revealing this week that around 800 have been infected since the outbreak. More than 8,000 people have died from the disease in total, including 500 health workers, and more than 20,000 have been infected. A vaccine could not come soon enough, and the acceleration of research has been astounding, with teams working on a solution or conducting trials in the UK, the US, Germany, Russia, Kenya, Switzerland and beyond. More via Ars Technica.
The auction has been closed.